3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
24
NIH
5
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Sarcoma, Kaposi
1
Sarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
AIDS-related Kaposi sarcoma
1
Interventions
Dexamethasone
45
Bortezomib
21
Lenalidomide
19
Cyclophosphamide
19
daratumumab
16
Calcium Dobesilate
13
Thalidomide
12
Melphalan
11
carfilzomib
9
Prednisone
7
pomalidomide
6
Peripheral Blood Stem Cell Transplantation
6
Doxorubicin
6
Filgrastim
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
auricularum
4
Vincristine
4
isatuximab
3
Interferon-alpha
3
Etoposide
3
selinexor
2
sargramostim
2
ixazomib
2
elotuzumab
2
cobimetinib
2
Steroids
2
Radiotherapy
2
Microarray Analysis
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Multiple Myeloma
×
Sirolimus
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled